Skip to main content
SpringerLink
Log in

The Glitazones, Lessons so Far

  • Chapter
Pharmacotherapy of Diabetes: New Developments

  • 1415 Accesses

Keywords: Pioglitazone, Rosiglitazone, Giltazones, Diabetes, Thiazolidinediones, Insulin Resistance.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adams M, Montague CT, Prins JB, et al. Activators of Peroxisome Proliferator-Activated Receptor gamma Have Depot-Specific Effects on Human Preadipocyte Differentiation. J Clin Invest. 1997; 100(12):3149–3153.

    Article  PubMed  Google Scholar 

  2. Vidal-Puig AJ, Considine RV, Jimenez-Liñan M, et al. Peroxisome proliferator-activated receptor gene expression in human tissues: effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest. 1997;99(10): 2416–2422.

    Article  PubMed  Google Scholar 

  3. Roden M, Price TB, Perseghin G, et al. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest. 1996;97:2859–2865.

    Article  PubMed  Google Scholar 

  4. Oakes ND, Thalen PG, Jacinto SM, et al. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. Diabetes. 2001;50:1158–1165.

    Article  PubMed  Google Scholar 

  5. Iwata M, Haruta T, Usui I, et al. Pioglitazone ameliorates tumor necrosis factor-alpha-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator-activated receptor-gamma. Diabetes. 2001;50:1083–1092.

    Article  PubMed  Google Scholar 

  6. Phillips SA, Ciaraldi TP, Kong AP, et al. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes 2003;52(3): 667–674.

    Article  PubMed  Google Scholar 

  7. Akazawa S, Sun F, Ito M, et al. Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care 2000;23:1067–1071.

    Article  PubMed  Google Scholar 

  8. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes. New Engl J Med. 1998;338(13): 867–872.

    Article  PubMed  Google Scholar 

  9. Nolan JJ, Bernhard L, Beerdsen P, et al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med. 1994;331(18):1188–1193.

    Article  PubMed  Google Scholar 

  10. Petersen KF, Krssak M, Inzucchi S, et al. Mechanism of troglitazone action in type 2 diabetes. Diabetes. 2000;49:827–831.

    Article  PubMed  Google Scholar 

  11. Maggs DG, Buchanan TA, Burant CF, et al. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998; 128(3):176–185.

    PubMed  Google Scholar 

  12. Shimabukuro M, Zhou YT, Lee Y, et al. Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J Biol Chem. 1998;273(6):3547–3550.

    Article  PubMed  Google Scholar 

  13. Unger RH. Lipotoxic diseases. Annual Rev of Medicine 2002;53:319–336.

    Article  Google Scholar 

  14. Yang L, An HX, Deng XL, et al. Rosiglitazone reverses insulin secretion altered by chronic exposure to free fatty acid via IRS-2-associated phosphatidylinositol 3-kinase pathway. Acta Pharmacologica Sinica. 2003;24(5):429–434.

    PubMed  Google Scholar 

  15. Finegood DT, McArthur MD, Kojwang D, et al. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 2001;50(5):1021–1029.

    Article  PubMed  Google Scholar 

  16. Buckingham RE, Al-Barazanji KA, Toseland CD, et al. Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes. 1998;47(8): 1326–1334.

    Article  PubMed  Google Scholar 

  17. Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride improves glycemic control in the treatment of patients with type 2 diabetes. Diabetes Care. 2000;23(11):1605–1611.

    Article  PubMed  Google Scholar 

  18. Kipnes M S, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med. 2001;111(1): 10–17.

    Article  PubMed  Google Scholar 

  19. Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther. 2000;22(12):1395–1409.

    Article  PubMed  Google Scholar 

  20. Rubin C, Egan J, Schneider R. Combination therapy with pioglitazone and insulin in patients with type 2 diabetes [abstract 0474]. Diabetes. 1999;48(suppl 1):A110.

    Google Scholar 

  21. Phillips LS, Grunberger G, Miller E, et al. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care. 2001;24(2):308–315.

    Article  PubMed  Google Scholar 

  22. Lebovitz LE, Dole JF, Patwardhan R, et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab. 2001;86(1):280–288.

    Article  PubMed  Google Scholar 

  23. Wolffenbuttel BHR, Gomist R, Squatrito S, et al. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med. 2000;17:40–47.

    Article  PubMed  Google Scholar 

  24. Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of Metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA. 2000;283(13):1695–1702.

    Article  PubMed  Google Scholar 

  25. Raskin P, Rendell M, Riddle MC, et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care. 2001;24(7):1226–1232.

    Article  PubMed  Google Scholar 

  26. Gerstein H, Yusuf S, Holman R, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose. Lancet 2006;368:1096–1105.

    Article  PubMed  Google Scholar 

  27. Prescribing information for pioglitazone. Takeda Pharmaceuticals. February, 2000.

    Google Scholar 

  28. Aoyama E, Tsujiuchi H, Asahi S, et al. In vitro studies on the metabolic pathways of pioglitazone [abstract 418-P]. Diabetes. 2001;50(suppl 2):A105.

    Article  Google Scholar 

  29. Fonseca V, Valiquett TR, Huang SM, et al. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. J Clin Endocrinol Metab. 1998;83(9):3169–76.

    Article  PubMed  Google Scholar 

  30. Prince MJ, Zagar AJ, Robertson KE. Effect of pioglitazone on HDL-C, a cardiovascular risk factor in type 2 diabetes [abstract 514-P]. Diabetes. 2001; 50(suppl 2):A128.

    Google Scholar 

  31. Dormany J, Charbonnel B, Eckland D, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study. Lancet. 2005;366:1279–1289.

    Article  Google Scholar 

  32. Li AC, Brown KK, Silvestre MJ, et al. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2000;106(4):523–531.

    Article  PubMed  Google Scholar 

  33. Collins AR, Noh G, Hsueh WA, et al. PPARγ ligands attenuate angiotensin-II accelerated atherosclerosis in male low density receptor deficient (LDLR-/-) mice[abstract 292-PP]. Diabetes. 2001;50(suppl 2): A72–A73.

    Google Scholar 

  34. Yoshimoto T, Naruse M, Shizume H, et al. Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy. Atherosclerosis. 1999; 145:333–340.

    Article  PubMed  Google Scholar 

  35. Minamikawa J, Tanaka S, Yamauchi M, et al. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 1998;83(5):1818–1820.

    Article  PubMed  Google Scholar 

  36. Koshiyama H, Shimono D, Kuwamura N, et al. Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 2001;86(7):3452–3456.

    Article  PubMed  Google Scholar 

  37. Choi SH, Choi DH, Ko YK, et al. Preventive effects of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes. ADA 63rd Scientific Sessions 2003;82-OR.

    Google Scholar 

  38. Schneider RL, Shaffer SJ. Long-Term Echocardiographic Assessment in patients with type 2 diabetes mellitus treated with pioglitazone [abstract 504-P]. Diabetes. 2000;49(suppl 1):A124.

    Google Scholar 

  39. Sutton MSJ, Dole JF, Rappaport EB. Rosiglitazone does not adversely affect cardiac structure or function in patients with type 2 diabetes [abstract 0438]. Diabetes. 1999;48(suppl 1):A102.

    Google Scholar 

  40. Actos (pioglitazone hydrochloride) [package insert]. Lincolnshire, Ill: Takeda Pharmaceuticals America, Inc; 2000.

    Google Scholar 

  41. Walker AB, Chattington PD, Buckingham RE, et al. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes. 1999;48(7):1448–1453.

    Article  PubMed  Google Scholar 

  42. Buchanan TA, Meehan WP, Jeng YY, et al. Blood pressure lowering by pioglitazone: evidence for a direct vascular effect. J Clin Invest. 1995;96:354–360.

    Article  PubMed  Google Scholar 

  43. Yang T, Michele DE, Park J, et al. Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney. Am J Physiol. 1999;277(6):F966–F973.

    PubMed  Google Scholar 

  44. Guan YF, Breyer MD. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int. 2001;60: 14–30.

    Article  PubMed  Google Scholar 

  45. Asano T, Wakisaka M, Yoshinari M, et al. Peroxisome proliferator-activated receptor gamma1 (PPARgamma1) expresses in rat mesangial cells and PPARgamma agonists modulate its differentiation. Biochim Biophys Acta. 2000;1497(1): 148–154.

    Article  PubMed  Google Scholar 

  46. Nicholas SB, Kawano Y, Wakino S, et al. Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells. Hypertension. 2001;37(2 part 2):722–727.

    PubMed  Google Scholar 

  47. Yoshimoto T, Naruse M, Nishikawa M, et al. Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am J Physiol. 1997;272(6):E989–E996.

    PubMed  Google Scholar 

  48. Nakamura T, Ushiyama C, Shimada N, et al. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. J Diabetes Complications. 2000;14(5):250–254.

    Article  PubMed  Google Scholar 

  49. Murata T, Hata Y, Ishibashi T, et al. Response of experimental retinal neovascularization to thiazolidinediones. Arch Ophthalmol. 2001;119(5): 709–717.

    PubMed  Google Scholar 

  50. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003;38(4):1008–1017.

    PubMed  Google Scholar 

  51. Sanyal AJ, Contos MJ, Sargeant C, et al. A randomized controlled pilot study of pioglitazone and vitamin E versus vitamin E for nonalcoholic steatohepatitis (abstract). Hepatology 2002;382A.

    Google Scholar 

  52. Promrat K, Lutchman G, Kleiner DE, et al. Pilot study of pioglitazone in nonalcoholic steatohepatitis (abstract). Gastroenterology, 2003;124(4) (Suppl 1):A708.

    Article  Google Scholar 

  53. Ghazeeri G, Kutteh WH, Bryer-Ash M, et al. Effect of rosiglitazone on spontaneous and clomiphene-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 2003;79(3):562–566.

    Article  PubMed  Google Scholar 

  54. Brettenthaler N, De Geyter C, Huber P, et al. Effect of Insulin Sensitizer Pioglitazone on Insulin resistance, Hyperadrongenism, and Ovulatory Dysfunction in Women with Polycystic Ovary Syndrome. J of Clin Endocrinol Metabolism. 2004; 89(8):3835–3840.

    Article  Google Scholar 

  55. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med. 1998;338(13):916–917.

    Article  PubMed  Google Scholar 

  56. Misbin, RI. Troglitazone-associated hepatic failure. Am J Med. 1999;130(4):330.

    Google Scholar 

  57. Forman LM, Simmons DA, Diamond RH. Hepatic failure in a patient taking rosiglitazone. Ann Intern Med. 2000;132(2):118–121.

    PubMed  Google Scholar 

  58. Maeda K. Hepatocellular injury in a patient receiving pioglitazone. Ann Inten Med 2001;135(4):306.

    Google Scholar 

  59. Al-Salman J, Arjomand H, Kemp DG, et al. Hepatocellular injury in a patient receiving rosiglitazone: a case report. Ann Intern Med. 2000;132(2): 121–124.

    PubMed  Google Scholar 

  60. Ravinuthala RS, Nori U. Rosiglitazone toxicity. Ann Intern Med. 2000;133(8):658.

    PubMed  Google Scholar 

  61. Donnelly R, Gray S, Idris I. Rosiglitazone and ankle swelling: an acute dose-dependent effect on endothelial permeability [abstract 275-OR]. Diabetes. 2001;50(suppl 1):A68.

    Google Scholar 

  62. Niemeyer NV, Janney LM. Thiazolidinedione-induced edema. Pharmacotherapy 2002;22(7): 924–929.

    Article  PubMed  Google Scholar 

  63. Gorson DM. Significant weight gain with rezulin therapy. Arch Intern Med. 1999;159:199.

    Article  Google Scholar 

  64. Thomas ML, Lloyd SJ. Pulmonary edema associated with rosiglitazone and troglitazone. Ann Pharmacother. 2001;35:123–124.

    Article  PubMed  Google Scholar 

  65. Shimizu H, Tsuchiya T, Sato N, et al. Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients. Diabetes Care. 1998;21:1470–1474.

    Article  PubMed  Google Scholar 

  66. King AB, Armstrong D. Characteristics of the patients who gain weight while on pioglitazone treatment [abstract 481-P]. Diabetes. 2001;50(suppl 1): A120.

    Google Scholar 

  67. Prescribing information for rosiglitazone. SmithKline Beecham Pharmaceuticals. February 2001.

    Google Scholar 

  68. Young MM, Squassante L, Wemer J, et al. Troglitazone has no effect on red cell mass or other erythropoietic parameters. Eur J Clin Pharmacol. 1999;55:101–104.

    Article  PubMed  Google Scholar 

  69. Dogterom P, Jonkman JHG, Vallance SE. Rosiglitazone: no effect on erythropoiesis or premature red cell destruction [abstract 0424]. Diabetes. 1999;48(suppl 1):A98.

    Google Scholar 

  70. Freed MI, Allen A, Jorkasky DK, et al. Systemic exposure to rosiglitazone is unaltered by food. Eur J Clin Pharmacol. 1999;55(1):53–56.

    Article  PubMed  Google Scholar 

  71. Carey RA, Liu Y. Pioglitazone does not markedly alter oral contraceptive or hormone replacement therapy pharmacokinetics [abstract 405-P]. Diabetes. 2000;49(suppl 1):A100.

    Google Scholar 

  72. Inglis AML, Miller AK, Culkin KT, et al. Rosiglitazone, a PPARg agonist, does not alter the pharmacokinetics of oral contraceptives [abstract 0443]. Diabetes. 2000;48(suppl1):A103.

    Google Scholar 

  73. Kermani A, Garg A. Thiazolidinedione-associated congestive heart failure and pulmonary edema. Mayo Clin Proc 2003;78(9):1088–1091.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, Diabetes & Metabolic Diseases Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, USA

    Monika Shirodkar

  2. 211 South Ninth Street, 19107, Philadelphia, PA, USA

    Serge Jabbour

Authors
  1. Monika Shirodkar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Serge Jabbour
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Aarhus University Hospital, Nørrebrogade 44, DK-8000, Aarhus, Denmark

    Carl Erik Mogensen MD

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Shirodkar, M., Jabbour, S. (2007). The Glitazones, Lessons so Far. In: Mogensen, C.E. (eds) Pharmacotherapy of Diabetes: New Developments. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-69737-6_10

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-69737-6_10

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-69736-9

  • Online ISBN: 978-0-387-69737-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation